News|Articles|April 23, 2024

Pharma Pulse 4/23/24: Drug Discount Programs Poised to Change with New Tech, SpecialtyRx Savings Navigator to Enhance Affordability & more

The latest news for pharma industry insiders.

LogiPharma Europe 2024: Envirotainer COO Discusses Reshaping Cold Chain Logistics and Adapting to Disruptions

In an interview with Pharma Commerce Editor Nicholas Saraceno, Niklas Adamsson, COO, Envirotainer, offers his thoughts on how changing customer needs are affecting cold chain logistics.

Drug Discount Programs Poised to Change with New Tech, Pharma Execs Survey Finds

It is somewhat mind-boggling in 2024 that more than one-third of pharma organizations still rely on manual entry of data into Excel spreadsheets to track duplicate discounts that can cost millions of dollars a year in lost revenue.

Meta, in Its Biggest A.I. Push, Places Smart Assistants Across Its Apps

Users of Instagram, Facebook, WhatsApp and Messenger will be able to turn to the new technology, powered by Meta’s latest artificial intelligence model, to obtain information and complete tasks.

CarelonRx launches SpecialtyRx Savings Navigator to Enhance Affordability, Management of Specialty Medications

CarelonRx announced the launch of SpecialtyRx Savings Navigator, a comprehensive approach to specialty medication savings across pharmacy and medical benefits. This solution aims to help employers plan for the specialty spend of tomorrow, while providing advocacy and care to their employees who utilize specialty medications today.

AliveCor on LinkedIn:

Ben Green, MD, our SVP of Services, shares his insights with Pharmaceutical Executive on how pharma and remote patient monitoring companies can work together to make decentralized clinical trials more commonly available. Read more below.

#ClinicalTrials #ClinicalResearch #RPM #Pharma #DCT

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.